NRXP Company Profile and Key Details
NRx Pharmaceuticals, Inc.
NRXP Stock Price Chart
Stock Price Today
NRx Pharmaceuticals, Inc. (NRXP) stock declined over -4.46%, trading at $3.00 on NASDAQ, down from the previous close of $3.14. The stock opened at $3.14, fluctuating between $2.87 and $3.18 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Company Information
| Employees | 2 |
| Beta | 1.27 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) stock price is $3.00 in the last trading session. During the trading session, NRXP stock reached the peak price of $3.18 while $2.87 was the lowest point it dropped to. The percentage change in NRXP stock occurred in the recent session was -4.46% while the dollar amount for the price change in NRXP stock was -$0.14.
The NASDAQ listed NRXP is part of Biotechnology industry that operates in the broader Healthcare sector. NRx Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Stephen H. Willard Esq.
Chief Executive Officer & Director
Mr. Riccardo Panicucci
CMC & Technical Operations Advisor
Dr. Carrie Carretta Ph.D.
Senior Vice President of Clinical Devel. & Medical Affairs
Dr. Philip T. Lavin Ph.D.
Chief Methodologist
Dr. Seth L. Van Voorhees Ph.D.
Chief Financial Officer & Treasurer
Prof. Daniel C. Javitt
Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael Kunz
Gen. Counsel & Corporation Sec.
Mr. Robert Besthof M.I.M.
Head of Operations, Chief Commercial & Patient Officer
Dr. Dennis K. McBride Ph.D.
Chief Strategy Officer & Senior Scientist
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer & Director
Mr. Riccardo Panicucci Ph.D.
Chief Technology Officer
Ms. Molly Cogan
Senior Director of Global Communications & Gov. Affairs
Suzanne Messere
Investor Relations
Mr. Matthew Patrick Duffy
Chief Bus. Officer
NRXP's closing price is 185.46% higher than its 52-week low of $1.10 where as its distance from 52-week high of $7.33 is -57.16%.
Number of NRXP employees currently stands at 2.
Official Website of NRXP is: https://www.nrxpharma.com
NRXP could be contacted at phone 484 254 6134 and can also be accessed through its website. NRXP operates from 1201 Orange Street, Wilmington, DE 19801, United States.
NRXP stock volume for the day was 397.41K shares. The average number of NRXP shares traded daily for last 3 months was 1.16M.
The market value of NRXP currently stands at $36.28M with its latest stock price at $3.00 and 12.09M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com